AU2019312296B2 - Pyridone A2R antagonists - Google Patents
Pyridone A2R antagonists Download PDFInfo
- Publication number
- AU2019312296B2 AU2019312296B2 AU2019312296A AU2019312296A AU2019312296B2 AU 2019312296 B2 AU2019312296 B2 AU 2019312296B2 AU 2019312296 A AU2019312296 A AU 2019312296A AU 2019312296 A AU2019312296 A AU 2019312296A AU 2019312296 B2 AU2019312296 B2 AU 2019312296B2
- Authority
- AU
- Australia
- Prior art keywords
- ome
- alkyl
- group
- cancer
- a2ar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711273P | 2018-07-27 | 2018-07-27 | |
| US62/711,273 | 2018-07-27 | ||
| PCT/US2019/043608 WO2020023846A1 (en) | 2018-07-27 | 2019-07-26 | Pyridone a2r antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019312296A1 AU2019312296A1 (en) | 2021-03-18 |
| AU2019312296B2 true AU2019312296B2 (en) | 2025-05-29 |
Family
ID=69182367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019312296A Active AU2019312296B2 (en) | 2018-07-27 | 2019-07-26 | Pyridone A2R antagonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12064433B2 (enExample) |
| EP (1) | EP3829581B1 (enExample) |
| JP (1) | JP7394831B2 (enExample) |
| KR (1) | KR102809468B1 (enExample) |
| CN (1) | CN112996509B (enExample) |
| AU (1) | AU2019312296B2 (enExample) |
| CA (1) | CA3107079A1 (enExample) |
| ES (1) | ES2982326T3 (enExample) |
| PL (1) | PL3829581T3 (enExample) |
| WO (1) | WO2020023846A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| JP2021183587A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3179320A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
| US11873291B2 (en) * | 2020-09-03 | 2024-01-16 | Immunesensor Therapeutics, Inc. | Quinoline cGAS antagonist compounds |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| KR20230158044A (ko) | 2021-03-18 | 2023-11-17 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| EP4341262A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
| TW202325279A (zh) | 2021-10-29 | 2023-07-01 | 美商阿克思生物科學有限公司 | HIF-2α抑制劑及其使用方法 |
| EP4486734A1 (en) | 2022-03-02 | 2025-01-08 | Immunesensor Therapeutics, Inc. | Quinoline cgas antagonist compounds |
| CN119156228A (zh) | 2022-05-02 | 2024-12-17 | 艾库斯生物科学有限公司 | 抗tigit抗体及其用途 |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| CN120091809A (zh) | 2022-10-20 | 2025-06-03 | 艾库斯生物科学有限公司 | Cd73化合物的冻干制剂 |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| EP4788432A1 (en) | 2023-10-06 | 2026-08-12 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
| WO2026064493A1 (en) * | 2024-09-20 | 2026-03-26 | University Of South Florida | Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure |
| AU2025271396B2 (en) * | 2024-10-30 | 2026-06-18 | Hanmi Pharm. Co., Ltd. | Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070219221A1 (en) * | 2006-03-17 | 2007-09-20 | Dewan Zeng | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| WO2016126570A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| WO2018136700A1 (en) * | 2017-01-20 | 2018-07-26 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006091898A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| WO2008156580A1 (en) * | 2007-06-13 | 2008-12-24 | Merck & Co., Inc. | Triazole derivatives for treating alzheimer's disease and related conditions |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| DK2820006T3 (da) * | 2012-02-29 | 2017-11-06 | Chemocentryx Inc | Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister |
| WO2015002994A2 (en) * | 2013-07-02 | 2015-01-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| CA3158951A1 (en) * | 2016-08-15 | 2018-02-22 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
-
2019
- 2019-07-26 AU AU2019312296A patent/AU2019312296B2/en active Active
- 2019-07-26 KR KR1020217005878A patent/KR102809468B1/ko active Active
- 2019-07-26 EP EP19841391.6A patent/EP3829581B1/en active Active
- 2019-07-26 CN CN201980064256.XA patent/CN112996509B/zh active Active
- 2019-07-26 US US17/263,016 patent/US12064433B2/en active Active
- 2019-07-26 PL PL19841391.6T patent/PL3829581T3/pl unknown
- 2019-07-26 ES ES19841391T patent/ES2982326T3/es active Active
- 2019-07-26 JP JP2021504283A patent/JP7394831B2/ja active Active
- 2019-07-26 WO PCT/US2019/043608 patent/WO2020023846A1/en not_active Ceased
- 2019-07-26 CA CA3107079A patent/CA3107079A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070219221A1 (en) * | 2006-03-17 | 2007-09-20 | Dewan Zeng | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| WO2016126570A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| WO2018136700A1 (en) * | 2017-01-20 | 2018-07-26 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102809468B1 (ko) | 2025-05-19 |
| WO2020023846A1 (en) | 2020-01-30 |
| AU2019312296A1 (en) | 2021-03-18 |
| US20210161898A1 (en) | 2021-06-03 |
| EP3829581B1 (en) | 2024-04-03 |
| PL3829581T3 (pl) | 2024-07-01 |
| EP3829581C0 (en) | 2024-04-03 |
| CA3107079A1 (en) | 2020-01-30 |
| CN112996509B (zh) | 2024-10-01 |
| EP3829581A4 (en) | 2022-04-27 |
| JP7394831B2 (ja) | 2023-12-08 |
| CN112996509A (zh) | 2021-06-18 |
| JP2021531314A (ja) | 2021-11-18 |
| EP3829581A1 (en) | 2021-06-09 |
| KR20210038642A (ko) | 2021-04-07 |
| ES2982326T3 (es) | 2024-10-15 |
| US12064433B2 (en) | 2024-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3829581B1 (en) | Pyridone a2r antagonists | |
| AU2022203515B2 (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| EP3618829B1 (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| EP3634417B1 (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| US12410170B2 (en) | 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds | |
| AU2019379808C1 (en) | Inhibitors of ARG1 and/or ARG2 | |
| US20230024438A1 (en) | Inhibitors of hif-2alpha | |
| HK40054296A (en) | Pyridone a2r antagonists | |
| HK40054296B (en) | Pyridone a2r antagonists | |
| HK40024629B (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| HK40024629A (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| HK40055891A (en) | Pyridone a2r antagonists | |
| HK40027765B (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| HK40027765A (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| HK40055891B (zh) | 吡啶酮a2r拮抗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |